Neurology

A greater proportion of atogepant-treated participants achieved at least a 50% reduction in mean monthly migraine days.

The study authors note that they cannot conclude that there is a causal relationship between the COVID-19 vaccines and any of the individual incidents of Bell palsy reviewed.

The FDA's green light for the Alzheimer medication is worrisome, as clinical trials proved inconclusive.

Peptides that cause migraine pain can influence insulin production in mice, possibly by regulating the amount of secreted insulin or by increasing the number of pancreatic cells that produce it.

This is the first time that the intravenous (IV) formulation of brivaracetam will be available for pediatric patients and is the only IV formulation approved for partial-onset seizures and this age group in nearly 7 years.

It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.

Ten quiz questions to assess your knowledge on common multiple sclerosis treatments.

Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.

Donanemab induced rapid amyloid plaque reduction at 24 weeks in patients with early symptomatic Alzheimer disease, with the most rapid clearance in patients with the most severe plaque burden at baseline.

Because there are no other available treatment options, Pamela Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families.

This recurring condition can require more firepower than OTC pain medications offer.

Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.

Patients treated with berubicin in clinical trials appeared to demonstrate positive responses, including 1 durable complete response in a phase 1 human clinical trial.

Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.

Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.

What community pharmacists need to know about migraine treatment and their role in educating and managing patients.

In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.

Despite the FDA's approval of aducanumab for the treatment of Alzheimer disease with mild cognitive impairments, it has been surrounded by questions.

Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.

Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.

Approved agents target calcitonin gene-related peptides to bring pain relief to affected patients.

Pamela Spicer, senior analyst with Datamonitor Healthcare, said aducanumab is a once-monthly infusion with a 6-month titration schedule.

An overview of CGRP antagonists approved as preventive therapy for migraine and recommendations for appropriate dosing and administration to patients.

Factors that need to be considered when determining patient candidacy for over-the-counter herbal products and nutritional supplements available as preventive therapy for migraine and recommendations for educating patients about their use.

Survival for patients with glioblastoma tumors is poor, with close to 75% of patients dying within 2 years of diagnosis and 95% dying within 5 years.

The updated label follows controversy surrounding aducanumab’s approval in June 2021, despite hesitation from experts on the drug’s efficacy.

Preventive therapies available for patients who require migraine prophylaxis and factors that impact treatment selection.

Jennifer L. Mazan, PharmD, describes the role of CGRP antagonists as acute migraine treatment and shares considerations for selecting and using these therapies.

The study authors said that these findings could be used to help identify healthy people who are at risk for the condition before they have symptoms.